China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Independent Director Annual Performance Report for 2025
As an independent director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu" or "the Company"), I have strictly adhered to the provisions of the Company Law, the Management Measures for Independent Directors of Listed Companies, the Articles of Association, and the Working System for Independent Directors of the Company. I have faithfully, diligently, and responsibly fulfilled my duties as an independent director, proactively understanding the Company's production and operational conditions, attending relevant Company meetings, fully leveraging my professional advantages and independent role, carefully reviewing all proposals presented to the Board of Directors, and expressing independent opinions, thereby effectively safeguarding the interests of the Company and its shareholders, especially minority shareholders.
I was elected as an independent director at the Company's first extraordinary general meeting of shareholders held on February 2, 2024, and I currently serve as the independent director and chair of the Audit Committee of the Board. Below is my performance report for 2025:
I. Basic Information
-
Basic Information of Independent Director
Mr. Sun Jian: Since July 2009, he has been teaching at the School of Accounting, Central University of Finance and Economics, serving as the Director of the Accounting Laboratory, Director of the Accounting Information Department, and Vice Dean of the School of Accounting. He is currently a professor and doctoral supervisor at the School of Accounting, Central University of Finance and Economics. He is a leading talent in accounting recognized by the Ministry of Finance (Phase IV) and a consulting expert for the National Accounting Information Standardization Technical Committee of the Ministry of Finance. Since 2015, he has served as an independent director for Panda Financial Holdings Co., Ltd., Founder Securities Underwriting and Sponsorship Co., Ltd., Scienjoy Holding Corporation, and Beijing Chang Development Industrial Operation Management Co., Ltd. He currently serves as an independent director for three domestic listed companies: Beijing Innotec Biotechnology Co., Ltd., Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd., and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. -
Self-Assessment of Independence
In accordance with the Management Measures for Independent Directors of Listed Companies and the Self-Regulatory Guidelines for Main Board Listed Companies No. 1 issued by the Shenzhen Stock Exchange, I have conducted a self-assessment of my independence as an independent director of the Company. In 2025, I did not hold any position in the Company other than that of independent director, nor did I hold any position in the Company's major shareholders. There are no interests or other relationships that may hinder my ability to make independent and objective judgments regarding the Company and its major shareholders. My appointment complies with the independence requirements set forth in the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.
II. Performance in 2025
- Attendance at Board and Shareholder Meetings
Independent Director Name | Total Board Meetings Required | Proxy Attendance | Absences | Attendance at Shareholder Meetings
--- | --- | --- | --- | ---
Sun Jian | 15 | 0 | 0 | No | 8
In 2025, the Company held a total of 15 board meetings, and I was able to attend all meetings on time as an independent director. I carefully reviewed the relevant materials submitted by the Company, listened to management's reports, actively participated in discussions, and expressed professional opinions and suggestions. I prudently exercised my voting rights, thoroughly reviewed and voted on all board proposals, and cast affirmative votes without opposing or abstaining from any board resolutions.